CTGov Compliance My Organizations

Compliance Rate

Compliance Rate 0%

Compliant submissions 0

Incompliant submissions 0

Total trials 0

My Organizations' Clinical Trials

Showing 14 of 14 entries

View as:

Phase I Study of Safety, Tolerability, and Pharmacokinetics of Viracept in HIV-1 Infected Children and Exposed Infants

Phase: N/A Priority: Normal

NCT ID: NCT00002164 Org: User:

Start: - End: - Due: -

A Study of Viracept in AIDS Patients With Cytomegalovirus Retinitis

Phase: N/A Priority: Normal

NCT ID: NCT00002169 Org: User:

Start: - End: - Due: -

A Study of Capravirine Plus VIRACEPT Plus Two Nucleoside Reverse Transcriptase Inhibitors in HIV-Infected Patients Who Failed Previous Anti-HIV Treatments

Phase: N/A Priority: Normal

NCT ID: NCT00006211 Org: User:

Start: 02/29/00 End: 04/30/01 Due: 04/30/02

A Pilot, Open-Label, Phase II, Randomized Study to Determine the Effects of Viracept on the Outcome of Cutaneous and Mucosal KS in AIDS Patients With CD4 <= 500 Cells/mm3

Phase: N/A Priority: Normal

NCT ID: NCT00002185 Org: User:

Start: - End: - Due: -

Effectiveness of a New Anti-HIV Drug (AG1549) Plus Viracept (Nelfinavir) Plus Combivir (Zidovudine/Lamivudine) in HIV-Infected Patients

Phase: N/A Priority: Normal

NCT ID: NCT00004999 Org: User:

Start: 08/31/99 End: - Due: -

Treatment With Nelfinavir or Efavirenz of HIV-Infected Patients Who Have Never Received Anti-HIV Drugs

Phase: N/A Priority: Normal

NCT ID: NCT00005000 Org: User:

Start: 12/31/99 End: - Due: -

A Study of Viracept in AIDS Patients With Mycobacterium Avium Complex Disease (MAC)

Phase: N/A Priority: Normal

NCT ID: NCT00002170 Org: User:

Start: - End: - Due: -

Safety and Effectiveness of Treating HIV-Positive Patients With an HIV Vaccine (Remune)

Phase: N/A Priority: Normal

NCT ID: NCT00005001 Org: User:

Start: - End: - Due: -

Combination Treatment Using Capravirine (AG1549), Nelfinavir, and Two Nucleoside Reverse Transcriptase Inhibitors in HIV Patients Who Failed Initial Combination Therapy

Phase: N/A Priority: Normal

NCT ID: NCT00004985 Org: User:

Start: 01/31/00 End: - Due: -

Safety and Effectiveness of a New Anti-HIV Drug (AG1549) in Combination With Other Anti-HIV Drugs in HIV-Infected Patients

Phase: N/A Priority: Normal

NCT ID: NCT00004998 Org: User:

Start: 11/30/99 End: - Due: -

A Study of Viracept in HIV-Positive Women

Phase: N/A Priority: Normal

NCT ID: NCT00002171 Org: User:

Start: - End: - Due: -

Effectiveness of Treating HIV-Positive Patients With an HIV Vaccine (Remune)

Phase: N/A Priority: Normal

NCT ID: NCT00005002 Org: User:

Start: - End: - Due: -

Safety and Effectiveness of 3 Anti-HIV Treatments in Patients Who Have Failed Previous Treatments Containing Nelfinavir

Phase: N/A Priority: Normal

NCT ID: NCT00006326 Org: User:

Start: 08/31/00 End: - Due: -

Viracept Expanded Access Program

Phase: N/A Priority: Normal

NCT ID: NCT00002165 Org: User:

Start: - End: - Due: -

Title	NCT ID	Organization	User	Status	Start Date	End Date	Reporting Due Date	Last Checked	User Role	Org Created
Phase I Study of Safety, Tolerability, and Pharmacokinetics of Viracept in HIV-1 Infected Children and Exposed Infants	NCT00002164	Agouron Pharmaceuticals	user2@example.com	None	-	-	-	-	-	2025-07-14
A Study of Viracept in AIDS Patients With Cytomegalovirus Retinitis	NCT00002169	Agouron Pharmaceuticals	user2@example.com	None	-	-	-	-	-	2025-07-14
A Study of Capravirine Plus VIRACEPT Plus Two Nucleoside Reverse Transcriptase Inhibitors in HIV-Infected Patients Who Failed Previous Anti-HIV Treatments	NCT00006211	Agouron Pharmaceuticals	user2@example.com	None	2000-02-29	2001-04-30	2002-04-30	-	-	2025-07-14
A Pilot, Open-Label, Phase II, Randomized Study to Determine the Effects of Viracept on the Outcome of Cutaneous and Mucosal KS in AIDS Patients With CD4 <= 500 Cells/mm3	NCT00002185	Agouron Pharmaceuticals	user2@example.com	None	-	-	-	-	-	2025-07-14
Effectiveness of a New Anti-HIV Drug (AG1549) Plus Viracept (Nelfinavir) Plus Combivir (Zidovudine/Lamivudine) in HIV-Infected Patients	NCT00004999	Agouron Pharmaceuticals	user2@example.com	None	1999-08-31	-	-	-	-	2025-07-14
Treatment With Nelfinavir or Efavirenz of HIV-Infected Patients Who Have Never Received Anti-HIV Drugs	NCT00005000	Agouron Pharmaceuticals	user2@example.com	None	1999-12-31	-	-	-	-	2025-07-14
A Study of Viracept in AIDS Patients With Mycobacterium Avium Complex Disease (MAC)	NCT00002170	Agouron Pharmaceuticals	user2@example.com	None	-	-	-	-	-	2025-07-14
Safety and Effectiveness of Treating HIV-Positive Patients With an HIV Vaccine (Remune)	NCT00005001	Agouron Pharmaceuticals	user2@example.com	None	-	-	-	-	-	2025-07-14
Combination Treatment Using Capravirine (AG1549), Nelfinavir, and Two Nucleoside Reverse Transcriptase Inhibitors in HIV Patients Who Failed Initial Combination Therapy	NCT00004985	Agouron Pharmaceuticals	user2@example.com	None	2000-01-31	-	-	-	-	2025-07-14
Safety and Effectiveness of a New Anti-HIV Drug (AG1549) in Combination With Other Anti-HIV Drugs in HIV-Infected Patients	NCT00004998	Agouron Pharmaceuticals	user2@example.com	None	1999-11-30	-	-	-	-	2025-07-14
A Study of Viracept in HIV-Positive Women	NCT00002171	Agouron Pharmaceuticals	user2@example.com	None	-	-	-	-	-	2025-07-14
Effectiveness of Treating HIV-Positive Patients With an HIV Vaccine (Remune)	NCT00005002	Agouron Pharmaceuticals	user2@example.com	None	-	-	-	-	-	2025-07-14
Safety and Effectiveness of 3 Anti-HIV Treatments in Patients Who Have Failed Previous Treatments Containing Nelfinavir	NCT00006326	Agouron Pharmaceuticals	user2@example.com	None	2000-08-31	-	-	-	-	2025-07-14
Viracept Expanded Access Program	NCT00002165	Agouron Pharmaceuticals	user2@example.com	None	-	-	-	-	-	2025-07-14

Compliance Rate

My Organizations' Clinical Trials

Appearance